ライフサイエンスコーパス: angiotensin II receptor blocker

1 enalapril, an ACE inhibitor, or L-158809, an angiotensin II receptor blocker.

2 n angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker.

3 the angiotensin II receptor, or losartan, an angiotensin II receptor blocker.

4 ngiotensin-converting enzyme inhibitor or an angiotensin II-receptor blocker.

5 angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.

6 AD2/3 and p38 signaling and was inhibited by angiotensin II receptor blockers.

7 mg/d) already receiving maximal therapy with angiotensin II receptor blockers.

8 ranged from 28% for beta-blockers to 65% for angiotensin II receptor blockers.

9 cal research suggests a protective effect of angiotensin II receptor blockers.

10 angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.

11 angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers.

12 angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (84.2%), and mineraloco

13 , an angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker (ACE-I/ARB), and lipid-l

14 rs, whereas angiotensin-converting enzyme or angiotensin II receptor blocker adherence was not associ

15 Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and aldosterone antagon

16 EPHESUS have added insight into the role of angiotensin II receptor blockers and aldosterone in the

17 significant differences in adherence between angiotensin II receptor blockers and angiotensin-convert

18 s and beta-blockers and highest adherence to angiotensin II receptor blockers and angiotensin-convert

19 but they support the clinical equivalence of angiotensin II-receptor blockers and ACE inhibitors in p

20 ectly compared the renoprotective effects of angiotensin II-receptor blockers and angiotensin-convert

21 The strength of evidence was rated high for angiotensin II-receptor blockers and statins, moderate f

22 Thiazide diuretics, angiotensin II receptor blockers, and ACE inhibitors may

23 angiotensin-converting enzyme inhibitors and angiotensin II-receptor blockers, and in patients with a

24 sonable to conclude that thiazide diuretics, angiotensin-II receptor blockers, and perhaps angiotensi

25 tunately, several modern drugs (eg, statins, angiotensin II receptor blockers, angiotensin-converting

26 lass, lower diastolic blood pressure, and no angiotensin II receptor blocker/angiotensin-converting e

27 of trials have tested the hypothesis that an angiotensin II receptor blocker (ARB) could be as effect

28 he association of statin, ACE inhibitor, and angiotensin II receptor blocker (ARB) use with pneumonia

29 tensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB), and diuretic medi

30 in II converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) presumably stimul

31 giotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARB), beta-blockers an

32 nsin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB).

33 otensin-converting-enzyme (ACE) inhibitor or angiotensin II-receptor blocker (ARB).

34 iotensin-converting enzyme inhibitors (ACEI)/angiotensin II receptor blockers (ARBs) at discharge and

35 ensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) for lowering blo

36 ensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) inhibit the reni

37 ensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), more effectivel

38 The benefit of angiotensin II-receptor blockers (ARBs) in heart failure

39 eatment with TGF-beta antagonists, including angiotensin II-receptor blockers (ARBs).

40 in-converting enzyme inhibitors (ACEIs), and angiotensin-II receptor blockers (ARBs) have been increa

41 ensin-converting-enzyme (ACE) inhibitors and angiotensin-II receptor blockers (ARBs) have specific re

42 Angiotensin II receptor blockers are beneficial in patie

43 dies of neutral endopeptidase inhibitors and angiotensin II receptor blockers are described.

44 titis, by degree of severity, among users of angiotensin II receptor blockers, as compared to non-use

45 s (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, aldoste

46 arge angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers, beta-blockers, and lip

47 s (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, calcium

48 angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, beta-blockers, thiazid

49 We evaluated the impact of 3 generic angiotensin II receptor blockers commercialization on ad

50 There was better adherence to angiotensin II receptor blockers compared with angiotens

51 the use of converting enzyme inhibitors and angiotensin II receptor blocker emphasizing doses, effic

52 te this variation, 7 of 8 classes (excluding angiotensin II receptor blockers) had at least 1 widely

53 angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers--have been shown to be

54 inhibitor (moderate-quality evidence) or an angiotensin II-receptor blocker (high-quality evidence)

55 The role of angiotensin II receptor blockers in patients with a syst

56 l studies are needed to assess the effect of angiotensin II receptor blockers in preclinical hypertro

57 The angiotensin-II-receptor blocker irbesartan is effective

58 It is unknown whether either the angiotensin-II-receptor blocker irbesartan or the calciu

59 e of angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers, lactates, renal replac

60 We aimed to assess the effect of the angiotensin II receptor blocker losartan on left ventric

61 in converting enzyme blocker, lisinopril, or angiotensin II receptor blocker, losartan, did not impro

62 e studies suggest that ACE inhibitors and/or angiotensin II receptor blockers may be effective treatm

63 Attenuation of TGF-beta signaling by angiotensin II receptor blockers may represent a mechani

64 sed case-control study indicates that use of angiotensin II receptor blockers might be associated wit

65 studies have suggested beneficial effects of angiotensin II receptor blockers on left ventricular hyp

66 The effect of angiotensin II receptor blockers on right ventricular (R

67 d mitral valves and we tested the effects of angiotensin II receptor blockers on TGF-beta signaling i

68 imed to determine the effect of losartan, an angiotensin II receptor blocker, on subpulmonary RV dysf

69 of either angiotensin-converting enzyme plus angiotensin II receptor blocker or angiotensin-convertin

70 and chronic use of statins or ACE inhibitors/angiotensin II receptor blockers) or plasma concentratio

71 t they may not be as effective as diuretics, angiotensin-II receptor blockers, or ACE inhibitors; how

72 dings challenge the generally held view that angiotensin II receptor blockers reduce cardiac hypertro

73 ative risk, 0.65 [95% CI, 0.49 to 0.88]) and angiotensin II-receptor blockers (relative risk, 0.77 [C

74 Treatment with the angiotensin II receptor blocker telmisartan improved glu

75 and early nephropathy to receive either the angiotensin II-receptor blocker telmisartan (80 mg daily

76 as provided new information into the role of angiotensin II receptor blocker therapy in patients who

77 Angiotensin II receptor blocker therapy may be protectiv

78 Angiotensin II receptor blocker therapy was associated w

79 ons, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use, smoking cessation;

80 hly mean rate of 100 adverse events for 1000 angiotensin II receptor blocker users before and after g

81 nd, parallel, randomized controlled trial of angiotensin II receptor blocker valsartan 160 mg twice d

82 vasodilating beta blocker (nebivolol) and an angiotensin II receptor blocker (valsartan) in adults wi

83 parative data on the long-term effects of an angiotensin II receptor blocker versus an angiotensin-co

84 reatitis and 61,637 controls, current use of angiotensin II receptor blockers was followed by a decre

85 n angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker were newly prescribed H-